



DEPARTMENT OF COMMERCE UNITED STAT Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, DC 20231

FILING DATE APPLICATION NO. FIRST NAMED INVENTOR ATTORNEY DOCKET NO.

09/077,817

Γ

09/14/98

CAPUT

D

IVD924

HM22/1001

PATENT DEPARTMENT SANOFI PHARMACEUTICALS INCORPORATED 9 GREAT VALLEY PARKWAY PO BOX 3026 MALVERN PA 19355

MCGARRY, S

PAPER NUMBER ART UNIT

EXAMINER

1635

DATE MAILED:

10/01/99

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



UNITED ATES DEPARTMENT OF COMMERCE

Patent and Trademark Office

COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

DEA/FCE-1994

SERIAL NUMBER FILING DA	E FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/077,817		

EXAMINER			
McGarry			
ART UNIT	PAPER NUMBER		
1635	12		
DATE MAILED:			

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

The reply filed 9/1/99 is not fully responsive to the communication mailed 6/30/99 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules or CRF Diskette Problem Report. Applicant submitted a CRF and a paper copy of the sequence listing on 9/1/99. The STIC systems branch corrected the CRF by adding the mandatory heading and subheadings for "Current Application Data". The submission of 9/1/99 does not correct deficiencies under 37 C.F.R. 1.821(d). Applicant is again directed to pages 19, 29, and 30, for example where sequences are disclosed and do not have their respective SEQ ID. Sequences in the Figures, 2a, 2b, 7a, and 7b, for example require sequence identifiers which must be disclosed in the "Brief Description of the Drawings" section of the specification. If these sequences are disclosed on the paper copy of the sequence listing and are contained in the CRF of the sequence listing then applicant can satisfy the sequence rules by amending the specification appropriately. If these sequences do not have sequence

identifiers applicant must supply a new paper copy and CRF in compliance with 37 C.F.R. 1.821-1.825.

Since the above-mentioned reply appears to be *bona fide*, applicant is given a TIME PERIOD of **ONE** (1) **MONTH** or **THIRTY** (30) **DAYS**, from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment.

EXTENSIONS OF THIS TIME LIMIT MAY BE GRANTED UNDER 37 CFR 1.136(a).

Sean McGarry

September 22, 1999

Bile

Application No.: <u>07/077,817</u> NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE